# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients

> **NCT01035801** · PHASE1 · TERMINATED · sponsor: **Biocon Limited** · enrollment: 20 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** IN-105
- **DRUG:** Insulin Lispro Injection

## Key facts

- **NCT ID:** NCT01035801
- **Lead sponsor:** Biocon Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08-21
- **Primary completion:** 2011-03-12
- **Final completion:** 2011-03-12
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** This study was temporarily paused due to an unanticipated bioanalytical issue.
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01035801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01035801, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01035801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*